Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Dermatologic 1CNS 1

Conditions

Melanoma 688Lymphoma, T-Cell, Cutaneous 116Keratosis, Actinic 109Skin Neoplasms 99Carcinoma, Non-Small-Cell Lung 81Mycosis Fungoides 79Neoplasm Metastasis 78Neoplasms 75Sezary Syndrome 74Lymphoma, Non-Hodgkin 72Leukemia, Lymphocytic, Chronic, B-Cell 65Lymphoma, Follicular 64Lymphoma, Large B-Cell, Diffuse 63Lymphoma, B-Cell, Marginal Zone 60Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Lymphoma, Mantle-Cell 59Uveal Melanoma 58Carcinoma, Renal Cell 58Carcinoma, Basal Cell 58Lymphoma, Large-Cell, Immunoblastic 56Hodgkin Disease 56Burkitt Lymphoma 55Lymphoma 52Lymphoma, Large-Cell, Anaplastic 50Waldenstrom Macroglobulinemia 44Multiple Myeloma 44Lymphoma, Extranodal NK-T-Cell 44Breast Neoplasms 44Immunoblastic Lymphadenopathy 43Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 41

Interventions

Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Histiocytoma × Dermatologic × Clear all
NCT01962103 2019-12-27

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

Celgene

Phase 1/2 Completed
107 enrolled 42 charts
CNSDermatologicSarcoma

Fibrosarcoma, Melanoma, Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Dermatofibrosarcoma, Histiocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡